{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=8",
    "query": {
      "intervention": "Amino Acid",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 16003,
    "total_pages": 1601,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T21:27:09.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01592370",
      "title": "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Hodgkin Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lirilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2012-08-02",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 32,
      "location_summary": "Clovis, California • Los Angeles, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592370"
    },
    {
      "nct_id": "NCT00678470",
      "title": "Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Moderate to Severe Psoriasis"
      ],
      "interventions": [
        {
          "name": "Intralesional Alefacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-09",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678470"
    },
    {
      "nct_id": "NCT00569673",
      "title": "Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "trabectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 71,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 37,
      "location_summary": "Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00569673"
    },
    {
      "nct_id": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "CRC",
        "Pancreatic Ductal Adenocarcinoma",
        "PDAC",
        "Gastrointestinal Cancer",
        "Metastatic Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6 regimen",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX regimen",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1130,
      "start_date": "2024-05-24",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445062"
    },
    {
      "nct_id": "NCT05904886",
      "title": "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 687,
      "start_date": "2023-09-14",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 34,
      "location_summary": "Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904886"
    },
    {
      "nct_id": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Lymphoma",
        "B Acute Lymphoblastic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Transformed Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Lister",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-04-19",
      "completion_date": "2037-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281809"
    },
    {
      "nct_id": "NCT03381599",
      "title": "Stem Cells After Peripheral Mobilization and Harvest",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stem Cells",
        "Orthopedic Disorder"
      ],
      "interventions": [
        {
          "name": "Filgrastim Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrews Research & Education Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "39 Years",
        "sex": "MALE",
        "summary": "19 Years to 39 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2018-03-28",
      "completion_date": "2019-09-04",
      "has_results": false,
      "last_update_posted_date": "2020-03-06",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 1,
      "location_summary": "Auburn, Alabama",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03381599"
    },
    {
      "nct_id": "NCT04938232",
      "title": "Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Relapsed Hodgkin's Disease, Adult",
        "Refractory Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-06-04",
      "completion_date": "2027-08-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04938232"
    },
    {
      "nct_id": "NCT02144155",
      "title": "Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Oxytocin: 24IU - 168 IU",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2012-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02144155"
    },
    {
      "nct_id": "NCT00004426",
      "title": "Leuprolide in Determining the Cause of Gonadotropin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "gonadotropin releasing hormone",
          "type": "DRUG"
        },
        {
          "name": "leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "9 Years to 18 Years"
      },
      "enrollment_count": 90,
      "start_date": "1994-08",
      "completion_date": "1998-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-11-18T21:27:09.014Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004426"
    }
  ]
}